Skip to main content

Peer Review reports

From: Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status

Original Submission
12 Dec 2014 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Publishing
13 Mar 2015 Editorially accepted
11 Apr 2015 Article published 10.1186/s12885-015-1191-3

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us